Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease

Characterising Alzheimer’s disease (AD) as a metabolic disorder of the brain is gaining acceptance based on the pathophysiological commonalities between AD and major metabolic disorders. Therefore, metabolic interventions have been explored as a strategy for brain energetic rescue. Amongst these, me...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2022-11, Vol.10 (11), p.2778
Main Authors: Ameen, Aishat O, Freude, Kristine, Aldana, Blanca I
Format: Article
Language:English
Subjects:
Alzheimer's disease
Animal models
butyrate
Care and treatment
Cell culture
Cognitive ability
decanoic acid
Development and progression
energy metabolism
Fatty acids
Health aspects
hiPSC
Lipids
Metabolic disorders
Mutation
neurodegeneration
Neurodegenerative diseases
octanoic acid
Pathology
Review
Risk factors
Rodents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Characterising Alzheimer’s disease (AD) as a metabolic disorder of the brain is gaining acceptance based on the pathophysiological commonalities between AD and major metabolic disorders. Therefore, metabolic interventions have been explored as a strategy for brain energetic rescue. Amongst these, medium-chain fatty acid (MCFA) supplementations have been reported to rescue the energetic failure in brain cells as well as the cognitive decline in patients. Short-chain fatty acids (SCFA) have also been implicated in AD pathology. Due to the increasing therapeutic interest in metabolic interventions and brain energetic rescue in neurodegenerative disorders, in this review, we first summarise the role of SCFAs and MCFAs in AD. We provide a comparison of the main findings regarding these lipid species in established AD animal models and recently developed human cell-based models of this devastating disorder.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10112778